Literature DB >> 11980940

Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Gaby E Pfyffer1, Frantiska Palicova, Sabine Rüsch-Gerdes.   

Abstract

The reliability of the novel BACTEC MGIT 960 pyrazinamide (PZA) kit (Becton Dickinson Microbiology Systems, Sparks, Md.) was assessed for testing of susceptibility of Mycobacterium tuberculosis to PZA. Results generated by the BACTEC MGIT 960 system (Becton Dickinson) were compared with those obtained with the BACTEC 460TB system. Extensive proficiency testing (phase I) and reproducibility testing (phase II) as well as susceptibility testing of blinded strains of M. tuberculosis from the Centers for Disease Control and Prevention (phase III) were performed prior to testing 58 strains isolated from clinical specimens (phase IV). After resolution of discrepant results obtained by the two BACTEC methods by two other laboratories which acted as independent arbiters (phase V), overall agreement of the BACTEC MGIT 960 system with the BACTEC 460TB system for PZA testing of phase IV strains was 96.6%. Between the two systems there was no statistically significant difference in time until results were obtained, i.e., 6.8 days (BACTEC MGIT 960) versus 5.4 days (BACTEC 460TB), the latter not counting the time required for a subculture with a growth index of 200, however. The new BACTEC MGIT PZA susceptibility testing procedure works equally well for inocula prepared from liquid (MGIT) and solid (Löwenstein-Jensen) cultures. PZA MGIT medium in plastic tubes yielded results equivalent to medium dispensed in glass tubes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11980940      PMCID: PMC130957          DOI: 10.1128/JCM.40.5.1670-1674.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms.

Authors:  S Sreevatsan; X Pan; Y Zhang; B N Kreiswirth; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

2.  Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Salfinger; L B Reller; B Demchuk; Z T Johnson
Journal:  Res Microbiol       Date:  1989 May-Jun       Impact factor: 3.992

3.  Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China.

Authors:  L Hou; D Osei-Hyiaman; Z Zhang; B Wang; A Yang; K Kano
Journal:  Epidemiol Infect       Date:  2000-04       Impact factor: 2.451

4.  Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Frantiska Palicova; Sabine Rüsch-Gerdes; Henri B Drugeon; Gaby E Pfyffer
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

5.  Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.

Authors:  L B Heifets; M D Iseman
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

6.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus.

Authors:  A Scorpio; Y Zhang
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

7.  Multicenter evaluation of the mycobacteria growth indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs.

Authors:  S Rüsch-Gerdes; C Domehl; G Nardi; M R Gismondo; H M Welscher; G E Pfyffer
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

8.  Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  W R Butler; J O Kilburn
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

9.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

10.  Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.

Authors:  C L Woodley; R W Smithwick
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  10 in total
  24 in total

1.  Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study.

Authors:  Salman Siddiqi; Altaf Ahmed; Sunil Asif; Digamber Behera; Mona Javaid; Jasmine Jani; Arora Jyoti; Radhika Mahatre; Dewanand Mahto; Elvira Richter; Camilla Rodrigues; Potharaju Visalakshi; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.

Authors:  Tsi-Shu Huang; Susan Shin-Jung Lee; Hui-Zin Tu; Wen-Kuei Huang; Yao-Shen Chen; Chung-Kai Huang; Shue-Ren Wann; Hsi-Hsun Lin; Yung-Ching Liu
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 3.  Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.

Authors:  Claudio Piersimoni; Armando Olivieri; Luca Benacchio; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

4.  Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.

Authors:  Sabine Rüsch-Gerdes; Gaby E Pfyffer; Manuel Casal; Maureen Chadwick; Salman Siddiqi
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

5.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

6.  Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings.

Authors:  I Kontsevaya; S Mironova; V Nikolayevskyy; Y Balabanova; S Mitchell; F Drobniewski
Journal:  J Clin Microbiol       Date:  2011-06-01       Impact factor: 5.948

7.  Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains.

Authors:  Luke T Daum; John D Rodriguez; Sue A Worthy; Nazir A Ismail; Shaheed V Omar; Andries W Dreyer; P Bernard Fourie; Anwar A Hoosen; James P Chambers; Gerald W Fischer
Journal:  J Clin Microbiol       Date:  2012-09-12       Impact factor: 5.948

8.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

9.  Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method.

Authors:  Claudio Scarparo; Paolo Ricordi; Giuliana Ruggiero; Paola Piccoli
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

10.  Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints.

Authors:  Stefan Niemann; Claudio U Köser; Sebastien Gagneux; Claudia Plinke; Susanne Homolka; Helen Bignell; Richard J Carter; R Keira Cheetham; Anthony Cox; Niall A Gormley; Paula Kokko-Gonzales; Lisa J Murray; Roberto Rigatti; Vincent P Smith; Felix P M Arends; Helen S Cox; Geoff Smith; John A C Archer
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.